Danbury’s Biodel Inc. says it signed up some 130 diabetics for the next leg of its ongoing study of the efficacy of its ultra-fast-acting synthetic insulin for regulating their blood sugar.
Biodel CEO Errol De Souza, M.D., said doubling patient enrollment for the Phase 2 trial is crucial to keeping the company on schedule with collecting and analyzing the top-line data in the third quarter.
The test patients who have type 1 diabetes were randomized to receive either Biodel’s proprietary BIOD-123 compound or Humalog to use as their mealtime insulin during an 18-week treatment period, the company said.
